Presentation Information
[3F-03T]The strategy to achieve high efficacy and safety in mRNA therapeutics
*Tetsuo Yoshida1,2, Rena Akahori2,3, Akiko Yanagiya2, Naoki Matsumoto2, Daichi Matsuura2, Hayato Sato2, Hiroaki Murakami2, Tomohiro Sawadaishi2, Yanwen Feng2, Jun Nihira2, Satoshi Abe2, Kazuyuki Nakashima2 (1. Axcelead, Inc. (Japan), 2. ARCALIS, Inc. (Japan), 3. Hitachi, Ltd. (Japan))
Keywords:
mRNA,CDMO,dsRNA,RNA Polymerase,5'CAP
Comment
To browse or post comments, you must log in.Log in